Market closedNon-fractional
Y-mAbs/YMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Y-mAbs
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Ticker
YMAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
100
Website
www.ymabs.com
Y-mAbs Metrics
BasicAdvanced
$499M
Market cap
-
P/E ratio
-$0.50
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$499M
Beta
0.65
Financial strength
Current ratio
6.15
Quick ratio
5.472
Long term debt to equity
0.295
Total debt to equity
1.191
Management effectiveness
Return on assets (TTM)
-9.87%
Return on equity (TTM)
-20.93%
Valuation
Price to revenue (TTM)
5.882
Price to book
5.02
Price to tangible book (TTM)
5.15
Price to free cash flow (TTM)
-28.262
Growth
Revenue change (TTM)
12.62%
Earnings per share change (TTM)
-70.73%
3-year revenue growth
47.87%
3-year earnings per share growth
-30.37%
What the Analysts think about Y-mAbs
Analyst Ratings
Majority rating from 7 analysts.
Y-mAbs Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
-14.59%
Net income
-$6.6M
633.33%
Profit margin
-33.16%
759.07%
Y-mAbs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.18
-$0.02
-$0.15
-
Expected
-$0.24
-$0.19
-$0.20
-$0.14
-$0.12
Surprise
-42.07%
-3.67%
-90.05%
10.46%
-
Y-mAbs News
AllArticlesVideos
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
GlobeNewsWire·4 days ago
Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm
Accesswire·3 weeks ago
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Y-mAbs stock?
Y-mAbs (YMAB) has a market cap of $499M as of July 05, 2024.
What is the P/E ratio for Y-mAbs stock?
The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of July 05, 2024.
Does Y-mAbs stock pay dividends?
No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Y-mAbs dividend payment date?
Y-mAbs (YMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Y-mAbs?
Y-mAbs (YMAB) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Y-mAbs stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.